Professor Ross Hannan
BSc (Hons) PhD FAHMS
Centenary Chair in Cancer Research and Deputy Dean Research
ANU College of Health and Medicine
T:
02 6125 6312
Areas of expertise
- Cancer Cell Biology 111201
- Cancer Genetics 111203
- Cancer Therapy (Excl. Chemotherapy And Radiation Therapy) 111204
- Haematological Tumours 111206
- Molecular Targets 111207
- Cell Development, Proliferation And Death 060103
- Signal Transduction 060111
- Biochemistry And Cell Biology 0601
Research interests
Cancer Biology
Cancer Therapeutics
Transcription
Chromatin and Epigenetics
Ribosome BIogenesis
High Throughput Functional Screening
Genomics
Biography
Professor Hannan is an internationally recognised laboratory scientist, whose work on ribosome biogenesis has led to new treatment paradigms in cancer, centred on drugs that activate nucleolar stress. He received his PhD from the University of Tasmania in 1994, before undertaking postdoctoral research in the USA. Since returning to Australia in 2000, he has held prominent positions at the Baker Medical Research Institute and the Peter MacCallum Cancer Centre in Melbourne. Recently Ross brought together multi-disciplinary teams of laboratory and clinician researchers, and forged industry collaborations to devise ‘first in class’ RNA polymerase I inhibitors, that are now in clinical trial for a range of heamatologic cancers. Hannan’s far-reaching contributions were recognised in his recent appointment as inaugural Centenary Chair in Cancer Research and Head of the ACRF Department of Cancer Biology and Therapeutics at John Curtin School of Medical Research, ANU.
Publications
- Kusnadi, E, Trigos, A, Cullinane, C et al. 2020, 'Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis', The EMBO Journal, vol. 39, no. 21, pp. -.
- Hannan, K, Hannan, R, Yan, S et al. 2020, 'The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serious ovarian cancer', British Journal of Cancer, vol. 124, pp. 616-627.
- Son, J, Hannan, K, Poortinga, G et al. 2020, 'rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461', Frontiers in Cell and Developmental Biology, vol. 8, pp. 1-14.
- Zaytseva, O, Friedrich, N, Guo, L et al. 2020, 'Transcriptional repression of Myc underlies the tumour suppressor function of AGO1 in Drosophila', Development, vol. 147, no. 11, pp. -.
- Chin, C, Antony, J, Ketharnathan, S et al. 2020, 'Cohesin mutations are synthetic lethal with stimulation of WNT signaling', eLife, vol. 9.
- Sanij, E, Hannan, K, Xuan, J et al. 2020, 'CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer', Nature Communications, vol. 11, no. 1, pp. -.
- Thejer, B, Adhikary, P, Kaur, A et al. 2020, 'PGRMC1 phosphorylation affects cell shape, motility, glycolysis, mitochondrial form and function, and tumor growth', BMC Molecular and Cell Biology, vol. 21, no. 1, pp. -.
- Chan, K, Blake, S, Zhu, H et al. 2020, 'A functional genetic screen defines the AKT-induced senescence signaling network', Cell Death and Differentiation, vol. 27, pp. 725-741.
- Gao, J, Jung, M, Mayoh, C et al. 2020, 'Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC-Driven Cancer Progression', Cancer Research, vol. 80, no. 17, pp. 3706-3718.
- Ferreira, R, Schneekloth Jr., J, Panov, K et al. 2020, 'Targeting the RNA Polymerase I Transcription for Cancer Therapy Comes of Age', Cells, vol. 9, no. 2.
- Franks, S, Firipis, K, Ferreira, R et al. 2020, 'Harnessing the self-assembly of peptides for the targeted delivery of anti-cancer agents', Materials Horizons, vol. 7, no. 8, pp. 1996-2010.
- Wagner, S, Herrmannová, A, Hronová, V et al. 2020, 'Selective Translation Complex Profiling Reveals Staged Initiation and Co-translational Assembly of Initiation Factor Complexes', Molecular Cell, vol. 79, no. 4, pp. 546-560.
- Khot, A, Brajanovski, N, Cameron, D et al 2019, 'First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study', Cancer Discovery, vol. 9, no. 8, pp. 1036-1049.
- Diesch, J, Bywater, M, Sanij, E et al 2019, 'Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation', Communications Biology, vol. 2, no. 39, pp. 1-14pp.
- Somers, K, Wen, V, Middlemiss, S et al. 2019, 'A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction', Oncogene, vol. 38, no. 20, pp. 3824-3842.
- Liu, P, Tee, A, Milazzo, G et al. 2019, 'The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35', Nature Communications, vol. 10.
- Shirokikh, N, Dutikova, Y et al 2019, 'Migration of Small Ribosomal Subunits on the 5' Untranslated Regions of Capped Messenger RNA', International Journal of Molecular Sciences, vol. 20, no. 18. pp. 4464
- Shirokikh, N, Dutikova, Y et al 2019, 'Migration of Small Ribosomal Subunits on the 5' Untranslated Regions of Capped Messenger RNA', International Journal of Molecular Sciences, vol. 20, no. 18. pp. 4464
- Chen, J, Siva, K, Rzymski, T et al. 2018, 'Small Molecule Screens Identify CDK8-Inhibitors As Candidate Diamond-Blackfan Anemia Drugs [Meeting Abstract]', Blood, vol. 132, no. 1.
- March, L, Willers, C, Ellis, J et al 2018, 'The Australian Arthritis and Autoimmune Biobank Collaborative (A3BC) Protocol', 2018 Australian Rheumatology Association Annual Scientific Meeting with the Rheumatology Health Professionals Association, ed. Jeff Szer, Wiley-Blackwell Publishing Asia, Australia, pp. 23-24.
- MacLachlan, K, Cuddihy, A, Hein, N et al 2018, 'Novel combination therapy targeting rDNA transcription and Histone Deacetylation Provides Effective Treatment for Multiple Myeloma, and Synergises in Bortezomib-Resistant MM', <>, p. 1945.
- Martin, C, Cullinane, C, Kirby, L et al 2018, 'Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance', International Journal of Cancer, vol. 142, no. 10, pp. 2139-2152.
- Udugama, M, Sanij, E, Voon, H et al 2018, 'Ribosomal DNA copy loss and repeat instability in ATRX-mutated cancers', PNAS - Proceedings of the National Academy of Sciences of the United States of America, vol. 115, no. 18, pp. 4737-4742pp.
- He, J, Soo, H, Evers, M et al. 2018, 'High-Content Imaging Approaches to Quantitate Stress-Induced Changes in Nucleolar Morphology', Assay and Drug Development Technologies, vol. 16, no. 6, pp. 320-332pp.
- Lawrence, M, Obinata, D, Sandhu, S et al 2018, 'Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy', European Urology, vol. 74, no. 5, pp. 562-572.
- Rebello, R, Kusnadi, E, Cameron, D et al 2017, 'Abstract B23: Inhibition of ribosomal RNA synthesis as a new therapeutic approach to treat advanced prostate cancer', Cancer Research, vol. 77, no. 6.
- Venugopal, P, Moore, S, Lawrence, D et al 2017, 'Self-reverting mutations partially correct the blood phenotype in a Diamond Blackfan Anemia patient', Haematologica, vol. 102, no. 12, pp. e506-e509pp.
- Hein, N, Hannan, K, D'Rozario, J et al. 2017, 'Inhibition of Pol I Transcription a New Chance in the Fight Against Cancer', Technology in Cancer Research and Treatment, vol. 16, no. 6, pp. 736-739pp.
- Lefebure, M, Tothill, R, Kruse, E et al. 2017, 'Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene', Nature Communications, vol. 8, pp. 1-10pp.
- Kerry, L, Pegg, E, Cameron, D et al. 2017, 'Selective inhibition of RNA polymerase I transcription as a potential approach to treat African trypanosomiasis', PLoS Neglected Tropical Diseases, vol. 11, no. 3, pp. -.
- Rebello, R, Pearson, R, Hannan, R et al 2017, 'Therapeutic approaches targeting MYC-Driven prostate cancer', GENES, vol. 8, no. 2, pp. 16pp.
- Hein, N, Cameron, D, Hannan, K et al. 2017, 'Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population', Blood, vol. 129, no. 21, pp. 2882-2895pp.
- Yan, S, Chan, K, Simpson, K et al. 2017, 'Abstract A24: A genome-wide RNAi screen identifies synthetic lethality of CX-5461 with homologous recombination repair deficiency in ovarian cancer', Molecular Cancer Research, vol. 15, no. 4.
- Hannan, R, Hein, N, Hannan, K et al. 2017, 'Abstract IA10: Drugging the ribosome at the level of synthesis and translation to treat solid and hematologic cancers', Cancer Research, vol. 77, no. 6.
- Yan, S, Frank, D, Son, J et al. 2017, 'The potential of targeting ribosome biogenesis in high-grade serous ovarian cancer', International Journal of Molecular Sciences, vol. 18, no. 1, pp. -.
- Moily, N, Ormsby, A, Stojilovic, A et al 2017, 'Transcriptional profiles for distinct aggregation states of mutant Huntingtin exon 1 protein unmask new Huntington's disease pathways', Molecular and Cellular Neuroscience, vol. 83, pp. 103-112pp.
- Hung, S, Lesmana, A, Peck, A et al. 2017, 'Cell cycle and growth stimuli regulate different steps of RNA polymerase I transcription', Gene, vol. 612, pp. 36-48pp.
- Hung, S, Lesmana, A, Peck, A et al. 2017, 'Cell cycle and growth stimuli regulate different steps of RNA polymerase I transcription', Gene, vol. 612, pp. 36-48.
- Rebello, R, Kusnadi, E, Cameron, D et al 2016, 'The dual inhibition of RNA Pol I transcription and PIM kinase as a new therapeutic approach to treat advanced prostate cancer', Clinical Cancer Research, vol. 22, no. 22, pp. 5539-5552pp.
- Guo, L, Zaysteva, O, Nie, Z et al 2016, 'Defining the essential function of FBP/KSRP proteins: Drosophila Psi interacts with the Mediator Complex to modulate MYC transcription and tissue growth', Nucleic Acids Research, vol. 44, no. 16, pp. 7646-7658.
- Quin, J, Chan, K, Devlin, J et al. 2016, 'Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling', Oncotarget, vol. 7, no. 31, pp. 49800-49818.
- Kang, J, Kusnadi, E, Ogden, A et al. 2016, 'Amino acid-dependent signaling via S6K1 and MYC is essential for regulation of rDNA transcription', Oncotarget, vol. 7, no. 31, pp. 48887-48904.
- Chan, K, Paavolainen, L, Hannan, K et al. 2016, 'Combining high-content imaging and phenotypic classification analysis of senescence-associated beta-galactosidase staining to identify regulators of oncogene-induced senescence', Assay and Drug Development Technologies, vol. 14, no. 7, pp. 416-428.
- Colebatch, A, Di Stefano, L, Hannan, R et al 2016, 'Clustered somatic mutations are frequent in transcription factor binding motifs within proximal promoter regions in melanoma and other cutaneous malignancies', Oncotarget, vol. 7, no. 41, pp. 66569-66585.
- Devlin, J, Hannan, K, Hein, N et al. 2016, 'Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma', Cancer Discovery, vol. 6, no. 1, pp. 59-70.
- Guo L., Zaysteva O., Nie Z, Mitchell N.C., Lee JEA. et al Hannan R.D., Levens D.L.,Quinn L.M. 2016, 'Defining the essential function of FBP/KSRP proteins: Drosophila Psi interacts with the mediator complex to modulate MYC transcription and tissue growth', Nucleic Acids Research, vol. 44, no. 16, pp. 7646-7658.
- Gilan, O, Diesch, J, Amalia, M et al 2015, 'PR55 alpha-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity', Oncogene, vol. 34, no. 10, pp. 1333-1339.
- Harrison, S, George, A & Hannan, R 2015, 'Commentary - A new window on cancer therapy? Targeting the nucleolus and ribosome biogenesis using the small molecule inhibitor of polymerase I transcription, CX-5461', International Journal of Hematologic Oncology, vol. 4, no. 2, pp. 61-65pp.
- Pereira, L, Mariadason, J, Hannan, R et al 2015, 'Implications of epithelial-mesenchymal plasticity for heterogeneity in colorectal cancer', Frontiers in Oncology, vol. 5, no. 13, pp. -.
- Lee, J, Mitchell, N, Zaytseva, O et al. 2015, 'Defective Hfp-dependent transcriptional repression of dMYC is fundamental to tissue overgrowth in Drosophila XPB models', Nature Communications, vol. 6, pp. 7404-7404.
- Kusnadi, E, Hannan, K, Hicks, R et al. 2015, 'Regulation of rDNA transcription in response to growth factors, nutrients and energy', Gene, vol. 556, no. 1, pp. 27-34.
- Sanji, E, Diesch, J, Lesmana, A et al 2015, 'A novel role for the pol I transcription factor ubtf in maintaining genome stability through the regulation of highly transcribed pol II genes', Genome Research, vol. 25, no. 2, pp. 201-212.
- Diesch, J, Hannan, R & Sanij, E 2015, 'Genome wide mapping of UBF binding-sites in mouse and human cell lines', Genomics Data, vol. 3, pp. 103-105.
- Poortinga, G, Quinn, L & Hannan, R 2015, 'Targeting RNA polymerase I to treat MYC-driven cancer', Oncogene, vol. 34, no. 4, pp. 403-412.
- Woods, S, Hannan, K, Pearson, R et al. 2015, 'The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy', Biochimica et Biophysica Acta - Gene Regulatory Mechanisms, vol. 1849, no. 7, pp. 821-829.
- Mitchell, N, Tchoubrieva, E, Chahal, A et al. 2015, 'S6 Kinase is essential for MYC-dependent rDNA transcription in Drosophila', Cellular Signalling, vol. 27, no. 10, pp. 2045-2053.
- Sjogren, S, Siva, K, Soneji, S et al 2015, 'Glucocorticoids improve erythroid progenitor maintenance and dampen Trp53 response in a mouse model of Diamond-Blackfan anaemia', British Journal of Haematology, vol. 171, no. 4, pp. 517-529.
- Lee, J, Mitchell, N, Zaytseva, O et al Levens D.L., Hannan R.D., and Quinn L.M. 2015, 'Defective Hfp-dependent transcriptional repression of dMYC is fundamental to tissue overgrowth in Drosophila XPB models', Nature Communications, vol. 6, no. 15, p. 7404.
- Mitchell, N, Tchoubrieva, E, Chahal, A et al Hannan R.D. and Quinn L.M. 2015, 'S6 Kinase is essential for MYC-dependent rDNA transcription in Drosophila', Cellular Signalling, vol. 27, no. 10, pp. 2045-2053.
- Quinn, L & Hannan, R 2015, 'MLK4 activates the NF-kB network to drive mesenchymal transition in glioblastoma', Translational Cancer Research, vol. 5, no. 6, pp. 6pp.
- Diesch, J, Hannan, R & Sanij, E 2014, 'Perturbations at the ribosomal genes loci are at the centre of cellular dysfunction and human disease', Cell and Bioscience, vol. 4, no. 1, pp. 43 (11pp).
- Diesch, J, Sanij, E, Gilan, O et al 2014, 'Widespread FRA1-Dependent Control of Mesenchymal Transdifferentiation Programs in Colorectal Cancer Cells', PLOS ONE (Public Library of Science), vol. 9, no. 3, pp. e88950-e88950.
- Drygin, D, O'Brien, S, Hannan, R et al 2014, 'Targeting the Nucleolus for cancer-specific activation of p53', Drug Discovery Today, vol. 19, no. 3, pp. 259-265.
- Quin, J, Devlin, J, Cameron, D et al. 2014, 'Targeting the nucleolus for cancer intervention', Biochimica et Biophysica Acta - Molecular Basis of Disease, vol. 1842, no. 6, pp. 802-816.
- Hamdane, N, Stefanovsky, V, Tremblay, M et al 2014, 'Conditional Inactivation of Upstream Binding Factor Reveals Its Epigenetic Functions and the Existence of a Somatic Nucleolar Precursor Body', PLoS Genetics, vol. 10, no. 8, pp. e1004505-e1004505.
- Foster, S, Porrello, E, Purdue, B et al 2013, 'Expression, Regulation and Putative Nutrient-Sensing Function of Taste GPCRs in the Heart', PLOS ONE (Public Library of Science), vol. 8, no. 5, pp. e64579-e64579.
- Chen, Y, Bui, A, Diesch, J et al 2013, 'A novel mouse model of atherosclerotic plaque instability for drug testing and mechanistic/therapeutic discoveries using gene and microRNA expression profiling', Circulation Research, vol. 113, no. 3, pp. 252-265.
- Sheppard, K, Cullinane, C, Hannan, K et al. 2013, 'Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors', European Journal of Cancer, vol. 49, no. 18, pp. 3936-3944.
- George, A, Purdue, B, Gould, C et al 2013, 'A functional siRNA screen identifies genes modulating angiotensin II-mediated EGFR transactivation', Journal of Cell Science, vol. 126, no. 23, pp. 5377-5390.
- George, A, Hannan, R & Thomas, W 2013, 'Unravelling the molecular complexity of GPCR-mediated EGFR transactivation using functional genomics approaches', The FEBS Journal, vol. 280, no. 21, pp. 5258-5268.
- Boglev, Y, Badrock, A, Trotter, A et al. 2013, 'Autophagy Induction Is a Tor- and Tp53-Independent Cell Survival Response in a Zebrafish Model of Disrupted Ribosome Biogenesis', PLoS Genetics, vol. 9, no. 2, pp. e1003279-e1003279.
- Bruhn, M, Pearson, R, Hannan, R et al 2013, 'AKT INDEPENDENT PI3 K SIGNALING IN CANCER EMERGING ROLE FOR SGK3', Cancer Management and Research, vol. 5, pp. 281-92.
- Hannan, K, Sanij, E, Rothblum, L et al. 2013, 'Dysregulation of RNA polymerase I transcription during disease', Biochimica et Biophysica Acta - Gene Regulatory Mechanisms, vol. 1829, no. 3-4, pp. 342-360.
- Bywater, M, Pearson, R, McArthur, G et al 2013, 'Dysregulation of the basal RNA polymerase transcription apparatus in cancer', Nature Reviews Cancer, vol. 13, no. 5, pp. 299-314.
- Hannan, R, Drygin, D & Pearson, R 2013, 'Targeting RNA polymerase I transcription and the nucleolus for cancer therapy', Expert Opinion on Therapeutic Targets, vol. 17, no. 8, pp. 873-878.
- Wall, M, Poortinga, G, Stanley, K et al. 2013, 'The mTORC1 Inhibitor Everolimus Prevents and Treats E mu-Myc Lymphoma by Restoring Oncogene-Induced Senescence', Cancer Discovery, vol. 3, no. 1, pp. 82-95.
- Hein, N, Hannan, K, George, A et al. 2013, 'The nucleolus: An emerging target for cancer therapy', Trends in Molecular Medicine, vol. 19, no. 11, pp. 643-654.
- Devlin, J, Hannan, K, Ng, P et al. 2013, 'AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo', The FEBS Journal, vol. 280, no. 21, pp. 5307-5316.
- Shortt, J, Martin, B, Hannan, K et al. 2013, 'Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas', Blood, vol. 121, no. 15, pp. 2964-2974.
- George, A, Purdue, B, Gould, K et al 2012, 'A Functional SiRNA Screening Approach to Investigate the Mechanism Underlying GPCR-mediated EGFR Transactivation in Malignancy', European Journal of Cancer, vol. 48, no. 5, pp. S149-S149.
- Pakay, J, Diesch, J, Gilan, O et al 2012, 'A 19S proteasomal subunit cooperates with an ERK MAPK-regulated degron to regulate accumulation of Fra-1 in tumour cells', Oncogene, vol. 31, no. 14, pp. 1817-1824.
- Bywater, M, Hannan, R, Poortinga, G et al 2012, 'Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53', Cancer Cell, vol. 22, no. 1, pp. 51-65.
- Quinn, L, Cranna, N, Lee, J et al 2012, 'Steroid hormones in Drosophila: how ecdysone coordinates developmental signalling with cell growth and division', in Hassan Abduljabbar (ed.), Steroids - Basic Science, InTech, Rijeka, Croatia, pp. 141-168.
- Hein, N, Sanij, E, Quin, J et al. 2012, 'The nucleolus and ribosomal genes in aging and senescence', in Tetsuji Nagata (ed.), Senescence, InTech, Rijeka, Croatia, pp. 171-203.
- Astle, M, Hannan, K, Ng, P et al. 2012, 'AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: Implications for targeting mTOR during malignancy', Oncogene, vol. 31, no. 15, pp. 1949-1962.
- Hannan, K, Sanij, E, Hein, N et al. 2011, 'Signaling to the Ribosome in Cancer-It Is More Than Just mTORC1', IUBMB Life, vol. 63, no. 2, pp. 79-85.
- Lee, R, House, C, Cristiano, B et al. 2011, 'Relative expression levels rather than specific activity plays the major role in determining in vivo AKT isoform substrate specificity', Enzyme Research, vol. 2011, no. 1.
- Jastrzebski, K, Hannan, K, House, C et al. 2011, 'A phospho-proteomic screen identifies novel S6K1 and mTORC1 substrates revealing additional complexity in the signaling network regulating cell growth', Cellular Signalling, vol. 23, no. 8, pp. 1338-1347.
- Smith, N, Chan, H, Qian, H et al. 2011, 'Determination of the exact molecular requirements for type 1 angiotensin receptor epidermal growth factor receptor transactivation and cardiomyocyte hypertrophy', Hypertension, vol. 57, no. 5, pp. 973-U217.
- Poortinga, G, Wall, M, Sanij, E et al 2011, 'C-MYC coordinately regulates ribosomal gene chromatin remodeling and Pol i availability during granulocyte differentiation', Nucleic Acids Research, vol. 39, no. 8, pp. 3267-3281.
- Drygin, D, Lin, A, Bliesath, J et al 2011, 'Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth', Cancer Research, vol. 71, no. 4, pp. 1418-1430.
- Cranna, N, Mitchell, N, Hannan, R et al 2011, 'Hfp, the Drosophila homolog of the mammalian c-myc transcriptional-repressor and tumor suppressor FIR, inhibits dmyc transcription and cell growth', Fly (Landes Bioscience), vol. 5, no. 2, pp. 129-133.
- #equal contribution #Chan, J, #Hannan, K, Riddell, K et al 2011, 'AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer', Science Signaling, vol. 4, no. 188.
- Lin, J, Mitchell, et al *Quinn L.M. and Hannan R.D. (*co-senior authors) 2011, 'Drosophila ribosomal protein mutants control tissue growth non-autonomously via effects on the prothoracic gland and ecdysone', PLoS Genetics, vol. 7, no. 12, pp. 1-18.
- George, A, Thomas, W & Hannan, R 2010, 'The renin-angiotensin system and cancer: Old dog, new tricks', Nature Reviews Cancer, vol. 10, no. 11, pp. 745-759.
- Wong, L, McGhie, J, Sim, M et al 2010, 'ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells', Genome Research, vol. 20, no. 3, pp. 351-360.
- Friedrich, N, Johanson, T, Cranna, N et al. 2010, 'Hfp inhibits Drosophila myc transcription and cell growth in a TFIIH/Hay-dependent manner', Development, vol. 137, no. 17, pp. 2875-2884.
- Bruhn, M, Hannan, R, Pearson, R et al. 2010, 'Second AKT: The rise of SGK in cancer signalling', Growth Factors, vol. 28, no. 6, pp. 394-408.
- Wall, M, Poortinga, G, Hannan, K et al. 2008, 'Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation', Blood, vol. 112, no. 6, pp. 2305-2317.
- Sanij, E, Poortinga, G, Sharkey, K et al. 2008, 'UBF levels determine the number of active ribosomal RNA genes in mammals', Journal of Cell Biology, vol. 183, no. 7, pp. 1259-1274.
- Jastrzebski, K, Hannan, K, Tchoubrieva, E et al. 2007, 'Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function', Growth Factors, vol. 25, no. 4, pp. 209-226.
- Cristiano, B, Chan, J, Hannan, K et al. 2006, 'A specific role for AKT3 in the genesis of ovarian cancer through modulation of G2-M phase transition', Cancer Research, vol. 66, no. 24, pp. 11718-11725.
- Poortinga, G, Hannan, K, Snelling, H et al. 2004, 'MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation', The EMBO Journal, vol. 23, no. 16, pp. 3325-3335.
- Hannan, K, Brandenburger, Y, Jenkins, A et al. 2003, 'mTOR-Dependent Regulation of Ribosomal Gene Transcription Requires S6K1 and Is Mediated by Phosphorylation of the Carboxy-Terminal Activation Domain of the Nucleolar Transcription Factor UBF', Molecular and Cellular Biology, vol. 23, no. 23, pp. 8862-8877.
- Hannan, K, Hannan, R, Smith, S et al. 2000, 'Rb and p130 regulate RNA polymerase I transcription: Rb disrupts the interaction between UBF and SL-1', Oncogene, vol. 19, no. 43, pp. 4988-4999.
- Hannan, K, Kennedy, B, Cavanaugh, A et al. 2000, 'RNA polymerase I transcription in confluent cells: Rb downregulates rDNA transcription during confluence-induced cell cycle arrest', Oncogene, vol. 19, no. 31, pp. 3487-3497.
- Hannan, K, Hannan, R & Rothblum, L 1998, 'Transcription by RNA polymerase I.', Frontiers in Bioscience, vol. 3, pp. d376-398.
- Hannan, R, Taylor, L, Cavanaugh, A et al. 1997, 'UBF and the regulation of ribosomal DNA transcription', in M Paule (ed.), Transcription of Ribosomal RNA genes by Eukaryotic RNA Polymerase I, Landes Bioscience, New York, pp. 221-232.
Projects and Grants
Grants information is drawn from ARIES. To add or update Projects or Grants information please contact your College Research Office.
- Ribosome biogenesis and disease (Primary Investigator)
- How novel ribosomal RNA gene repeat variants drive cellular function (Secondary Investigator)
- NHMRC Equipment Grant 2021: ACDT Equipment - Linked to ARIES ID 39296 (Primary Investigator)
- The nucleolar stress response at the centre of the malignant phenotype (Secondary Investigator)
- BioTek MultiFlo FX with AMX Module and Wash Module (see 37697) (Primary Investigator)
- Targeting cancer metabolism to reduce metastases (Secondary Investigator)
- TARGETING RNA POLYMERASE I TO TREAT CANCER (Primary Investigator)
- Harnessing the Nucleolar Surveillance Response to Treat Disease (Primary Investigator)
- Identifying therapeutics which can be repurposed for the treatment of Myelodysplastic Syndrome and other Bone Marrow Failure Disorders (Secondary Investigator)
- Determining how FUBP1 drives Oligodendroglioma to develop better treatments for primary brain cancer (Secondary Investigator)
- Novel Therapies for Osteosarcoma: RNA Pol I Inhibitors (Secondary Investigator)
- IntelliCyt iQue QMAX Refill Module (see 34173) (Primary Investigator)
- Mechanisms and targets of protein synthesis dysregulation in cancer (Secondary Investigator)
- How ribosomal protein loss affects cell fate (Primary Investigator)
- Therapeutic targeting of ribosome biogenesis in cancer and ribosomopathies (Primary Investigator)
- The ACRF Department of Cancer Biology and Therapeutics (Primary Investigator)
- Regulation of ribosomal gene chromatin during malignant transformation (Primary Investigator)
- Development of broad spectrum, non-genotoxic cancer treatments for acute myeloid leukaemias and multiple myeloma (Primary Investigator)
- Novel combination therapies targeting the ribosome to treat prostate cancer (PC) (Primary Investigator)
- The Australian Diamond-Blackfan Anaemia Program (ADBA) - including CRISPR and Therapeutic program (Primary Investigator)
- Senior Research Fellowship B (Primary Investigator)
- Oncogenic signaling and cancer therapy - External led (Secondary Investigator)
- Centenary Chair in Cancer Research (Primary Investigator)
